ACT PAROXETINE 30 MG
PAROXETINE (PAROXETINE HYDROCHLORIDE) : 30 MG · DIN 02262762 · ACTAVIS PHARMA COMPANY
Health Canada status: CANCELLED POST MARKET
What is ACT PAROXETINE?
ACT PAROXETINE 30 MG contains PAROXETINE (PAROXETINE HYDROCHLORIDE) : 30 MG. It is listed in the Health Canada Drug Product Database under DIN 02262762, held by ACTAVIS PHARMA COMPANY, supplied as TABLET for ORAL administration. Health Canada currently lists it as cancelled post market, status dated 21-Oct-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is ACT PAROXETINE used for?
Major Depressive Disorder (MDD), Obsessive-Compulsive Disorder (OCD), Panic Disorder, Social Phobia (Social Anxiety Disorder), Generalized Anxiety Disorder (GAD), Posttraumatic Stress Disorder (PTSD).
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02262762 |
|---|---|
| Brand name | ACT PAROXETINE |
| Generic / active ingredient | PAROXETINE (PAROXETINE HYDROCHLORIDE) : 30 MG |
| Manufacturer | ACTAVIS PHARMA COMPANY |
| Strength | 30 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | N06AB05 PAROXETINE |
| AHFS class | 28:16.04.20 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 21-Oct-2020 |
| Original market date | 2005-03-14 00:00:00 |
How is it administered?
Administered as a single daily dose, usually in the morning with food. Gradual dose reduction is recommended for discontinuation. Dosage varies by indication (10mg to 50mg/day).
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided text (standard reference to Part I Summary Product Information usually implies 15-30°C).
How is it supplied?
Not explicitly detailed in the provided text beyond strengths (10 mg, 20 mg, 30 mg). Typically available in bottles or blisters.
Contraindications
Hypersensitivity to paroxetine; Concomitant use with MAOIs (including linezolid, methylene blue), thioridazine, or pimozide.
Warnings and precautions
Potential for behavioral/emotional changes including self-harm; risk of Serotonin Syndrome; bone fracture risk; abnormal bleeding; hyponatremia; angle-closure glaucoma; seizure risk.
What can be used instead?
Other Canadian products sharing ATC code N06AB05 PAROXETINE. 51 of 106 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| AG-PAROXETINE TABLETS | 10 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510480 |
| AG-PAROXETINE TABLETS | 20 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510499 |
| AG-PAROXETINE TABLETS | 30 MG | TABLET | ANGITA PHARMA INC. | MARKETED | DIN 02510510 |
| APO-PAROXETINE | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02240907 |
| APO-PAROXETINE | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02240908 |
| APO-PAROXETINE | 30 MG | TABLET | APOTEX INC | MARKETED | DIN 02240909 |
| AURO-PAROXETINE | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383276 |
| AURO-PAROXETINE | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383284 |
| AURO-PAROXETINE | 30 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02383292 |
| BIO-PAROXETINE | 10 MG | TABLET | BIOMED PHARMA | MARKETED | DIN 02444909 |
Who else supplies PAROXETINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. PAROXETINE appears in 4233 registered pack listings across 13 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.